Clinical testing is the process of evaluating medical treatments, drugs, devices, or procedures in human volunteers to determine whether they are safe and effective. It is the required step between laboratory research and a product reaching patients. The full process from initial discovery to regulatory approval typically takes 10 to 15 years and costs between $897 million and $1.9 billion per approved drug, with overall success rates of only about 10 to 21 percent.
Clinical Trials vs. Observational Studies
Clinical testing falls into two broad categories. Clinical trials actively test an intervention, such as a new drug, surgical technique, diet, or medical device like a pacemaker. Researchers assign participants to specific treatments, measure outcomes, and compare results. Observational studies, by contrast, monitor people in their normal settings without introducing any intervention. Researchers simply track health data over time to spot patterns. For example, an observational study might follow a group of older adults, recording their exercise habits and memory performance over a year to see whether physical activity correlates with cognitive health.
Observational studies can reveal associations that point toward promising treatments, but they cannot prove cause and effect. That proof comes from clinical trials, which are the primary way researchers confirm that a new treatment actually works and is safe enough for widespread use.
The Four Phases of Clinical Trials
Before any human testing begins, a treatment goes through preclinical research, typically involving laboratory work and animal studies. If results look promising, the developer submits an Investigational New Drug (IND) application to the FDA. This application must include animal safety data, manufacturing details, and detailed plans for the proposed human studies. The FDA then has 30 calendar days to review the submission and confirm that participants won’t face unreasonable risk. Only after that waiting period can human trials begin.
Phase I: Safety
A small group of 20 to 80 volunteers receives the treatment for the first time. The goal is straightforward: find out whether the treatment is safe, identify side effects, and determine appropriate dosing. These participants are often healthy volunteers rather than patients with the target condition.
Phase II: Effectiveness
If Phase I shows acceptable safety, the trial expands to a larger group, typically several hundred people who have the condition the treatment targets. Researchers begin measuring whether the treatment actually works while continuing to monitor side effects. Many drugs fail at this stage because they show limited benefit or unexpected problems in a real patient population.
Phase III: Large-Scale Confirmation
Phase III trials enroll hundreds to thousands of participants across multiple locations. These studies generate the large-scale evidence needed for regulatory approval, comparing the new treatment against existing standard treatments or placebos. This phase confirms effectiveness, monitors side effects in a diverse population, and collects the data the FDA requires to decide whether to approve the drug for public use.
Phase IV: Post-Approval Monitoring
Even after a drug reaches the market, testing continues. Phase IV studies track long-term safety and effectiveness in the general population, where the drug is used by a much wider and more varied group of people than any trial could enroll. Rare side effects that didn’t appear during earlier phases sometimes surface here.
The drop-off between phases is steep. Studies examining 21st-century drug development have found that overall clinical trial success rates range from about 7 to 20 percent, depending on the disease area and how success is measured. Most experimental treatments that enter human testing never reach pharmacy shelves.
How Trials Minimize Bias
The gold standard design for clinical trials is the double-blind, randomized controlled trial. In this setup, participants are randomly assigned to either the treatment group or a control group. The control group typically receives a placebo (an inactive substance that looks identical to the real treatment) or the current standard treatment. “Double-blind” means neither the participants nor the researchers interacting with them know who is receiving which treatment. This prevents expectations from influencing the results on either side.
Randomization ensures that the groups are as similar as possible at the start of the trial, so any difference in outcomes can be attributed to the treatment rather than to pre-existing differences between the groups. Without these controls, it would be difficult to separate the actual effects of a drug from the natural course of a disease or the psychological boost that comes from simply receiving care.
Eligibility and Enrollment
Every clinical trial has a protocol that spells out exactly who can participate. These eligibility criteria vary by study and can include factors like age, sex, type and stage of disease, previous treatments, and other existing health conditions. Some trials seek “patient volunteers,” people who have the condition being studied. Others need “healthy volunteers” who serve as a baseline for comparison.
You can search for trials by topic, location, and age through registries like ClinicalTrials.gov. If you meet the initial criteria listed for a study, the next step is a screening process where the research team evaluates whether you’re a good fit. This screening often involves medical tests, a review of your health history, and a detailed conversation about what the trial involves.
Informed Consent and Safety Oversight
Before you join any clinical trial, you go through an informed consent process that covers eight required elements: a description of what the study involves, the risks and discomforts, potential benefits, alternative treatments available to you, how your confidentiality will be protected, compensation and medical treatment if you’re injured, who to contact with questions, and a clear statement that participation is voluntary. You can withdraw at any time without penalty.
Behind the scenes, an independent body called an Institutional Review Board (IRB) must approve every clinical trial before it begins. The IRB reviews the study design, consent materials, and safety protocols. Its job is to protect participants’ rights and welfare, and it has the authority to require changes to a study or shut it down entirely. The IRB also ensures that the consent process is free from coercion or undue pressure.
For large-scale trials, a separate Data Monitoring Committee independently reviews incoming results while the study is still running. Federal regulations require this for large trials involving human subjects. If the data reveals serious safety concerns, or if the treatment is so clearly effective that it would be unethical to keep giving a placebo to the control group, the committee can recommend stopping the trial early.
What Happens After Testing
When a treatment completes Phase III with positive results, the developer submits all trial data to the FDA for review. The agency evaluates whether the benefits outweigh the risks for the intended patient population. If approved, the treatment can be manufactured and prescribed. Phase IV monitoring then tracks how the treatment performs in the real world over months and years.
The entire journey is long and uncertain. The 10-to-15-year timeline includes years of preclinical work before human testing even starts, followed by the sequential phases that each take months to years to complete. The escalating costs, which now routinely exceed $1 billion per approved drug, reflect both the complexity of the science and the high failure rate. For every drug that makes it through, many more are quietly abandoned after showing disappointing results or unacceptable side effects in one of the trial phases.